regulatory
confidence high
sentiment negative
materiality 0.90
Salarius receives Nasdaq delisting notice for bid price non-compliance; appeal planned
Decoy Therapeutics Inc.
- Nasdaq notified Salarius on Dec 31, 2025 that bid price closed below $1.00 for 30 consecutive days.
- Company ineligible for 180-day cure period due to reverse stock split within prior year.
- Unless appeal filed by Jan 7, 2026, trading suspended Jan 9, 2026 and Form 25-NSE filed.
- Salarius intends to appeal to Nasdaq Hearings Panel to stay suspension and present compliance plan.
- No assurance that securities will remain listed on Nasdaq Capital Market.